ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Singapore's Temasek expands investment in biotech companies

Sovereign fund leads UK Glympse Bio's $46.7m fundraising

Singapore state-owned investment company Temasek has targeted multiple biotechnology companies for investments.   © Reuters

SINGAPORE -- UK-headquartered Glympse Bio has raised $46.7 million in an oversubscribed series B funding round from a slew of investors, including Singapore state-owned investment company Temasek.

The investment from Temasek marks a continuation of the fund's interest in biotechnology investments.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more